|
1
|
Revised response criteria for malignant lymphoma.
|
J Clin Oncol
|
2007
|
22.19
|
|
2
|
The role of FDG-PET scans in patients with lymphoma.
|
Blood
|
2007
|
2.14
|
|
3
|
Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study.
|
Blood
|
2009
|
2.09
|
|
4
|
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET.
|
Blood
|
2011
|
1.55
|
|
5
|
Role of positron emission tomography in lymphoma.
|
J Clin Oncol
|
2005
|
1.26
|
|
6
|
Improvement of early 18F-FDG PET interpretation in diffuse large B-cell lymphoma: importance of the reference background.
|
J Nucl Med
|
2010
|
1.09
|
|
7
|
First demonstration of leukemia imaging with the proliferation marker 18F-fluorodeoxythymidine.
|
J Nucl Med
|
2008
|
1.08
|
|
8
|
Scintigraphic detection of benign struma ovarii in a hyperthyroid patient.
|
J Clin Endocrinol Metab
|
2005
|
0.97
|
|
9
|
Single photon emission computed tomography (SPECT) should be routinely performed for the detection of parathyroid abnormalities utilizing technetium-99m sestamibi parathyroid scintigraphy.
|
Clin Nucl Med
|
2009
|
0.86
|
|
10
|
Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine.
|
Clin Cancer Res
|
2008
|
0.85
|
|
11
|
Imaging in early-stage Hodgkin's lymphoma.
|
N Engl J Med
|
2010
|
0.83
|
|
12
|
Corn oil emulsion: a simple cholecystagogue for diagnosis of chronic acalculous cholecystitis.
|
J Nucl Med
|
2005
|
0.82
|
|
13
|
Measuring granulocyte and monocyte accumulation at malignant lymphoma sites.
|
J Clin Oncol
|
2008
|
0.82
|
|
14
|
Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.
|
J Nucl Med
|
2006
|
0.80
|
|
15
|
Is there a correlation between symptoms and bone scintigraphic findings in patients with complex regional pain syndrome?
|
Ann Nucl Med
|
2012
|
0.78
|
|
16
|
Can the interim fluorodeoxyglucose-positron emission tomography standardized uptake value be used to determine the need for residual mass biopsy after dose-dense immunochemotherapy for advanced diffuse large B-cell lymphoma?
|
J Clin Oncol
|
2010
|
0.77
|
|
17
|
Radioimmunotherapy with 131I-rituximab: what we know and what we don't know.
|
Cancer Biother Radiopharm
|
2003
|
0.76
|
|
18
|
Modeling combined radiopharmaceutical therapy: a linear optimization framework.
|
Technol Cancer Res Treat
|
2009
|
0.76
|
|
19
|
Nasopharyngeal squamous cell carcinoma metastatic to psoas muscle.
|
Clin Nucl Med
|
2010
|
0.76
|
|
20
|
18 F-fluorothymidine uptake in follicular lymphoma and error-prone DNA repair.
|
EJNMMI Res
|
2014
|
0.75
|
|
21
|
Diagnosis of mesenteric panniculitis in the multi-detector computed tomography era. Association with malignancy and surgical history.
|
Saudi Med J
|
2017
|
0.75
|
|
22
|
Standardization of quantitative single photon emission computed tomography in control individuals and in patients with condylar hyperplasia.
|
Nucl Med Commun
|
2014
|
0.75
|
|
23
|
PET/CT with 18F-FLT is unlikely to cause significant hepatorenal or hematologic toxicity.
|
J Nucl Med
|
2010
|
0.75
|
|
24
|
Current and future aspects of nuclear molecular therapies: a model of theranostics.
|
Methods
|
2011
|
0.75
|